Groundbreaking CD19 Binders For Immunotherapy Innovation
Pioneering the Future with State-of-the-Art Binder Discovery
Verismo isn’t just leading the way; we’re redefining it. Our groundbreaking binder discovery is a result of our exclusive research collaboration with the University
of Pennsylvania. This partnership led to two anti-CD19 binders, one of which is called DS191, that rival those available in the commercial market.
Unleashing the Powerful Combination of Novel Binders and the KIR-CAR Platform
Verismo isn’t just innovating; we’re revolutionizing. Harnessing the power of our DS191 binder, we’ve crafted the SynKIR-310, our product candidate for patients battling relapsed or refractory diffuse large B-cell lymphoma (DLBCL) post-CAR T therapy.
Advancing Precision Medicine Together
True innovation is a collective endeavor. Verismo Therapeutics welcomes the opportunity to collaborate with other organizations to enable new treatments through our new CD19 binders.